Overexpression of phosphorylated ATF2 and STAT3 in eccrine porocarcinoma and eccrine poroma

Journal of Dermatological Science

Volumn 49, Issue 2, 2008, Pages 170-173

  Chen, Si Yuan ^a,b   Takeuchi, Satoshi ^a   Urabe, Kazunori ^a   Kido, Makiko ^a   Hayashida, Sayaka ^a   Tomoeda, Hiroto ^a   Uchi, Hiroshi ^a   Dainichi, Teruki ^a   Takahara, Masakazu ^a   Shibata, Satoko ^a   Furue, Masutaka ^a   Moroi, Yoichi ^a   Tu, Ya Ting ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

ATF2 (AP 1); Eccrine porocarcinoma; Eccrine poroma; STAT3

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CYCLIN D1; CYCLIN D2; GELATINASE A; STAT3 PROTEIN; VASCULOTROPIN;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; ECCRINE POROCARCINOMA; ECCRINE POROMA; HUMAN; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SWEAT GLAND CARCINOMA; TRANSCRIPTION REGULATION;

ACROSPIROMA, ECCRINE; ACTIVATING TRANSCRIPTION FACTOR 2; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL NUCLEUS; ECCRINE GLANDS; FEMALE; HUMANS; KERATINOCYTES; MALE; MIDDLE AGED; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; SWEAT GLAND NEOPLASMS; UP-REGULATION;

EID: 37349059314     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2007.08.001     Document Type: Letter

References (10)

1. Mehregan A.H., Hasimoto K., and Homayoon R. Eccrine adenocarcinoma-a clinicopathologic study of 35 cases. Arch Dermatol 119 (1983) 104-114
2. Ichihashi N., and Kitajima Y. Loss of heterozygosity of adenomatous polyposis coli gene in cutaneous tumors as determined by using polymerase chain reaction and paraffin section preparations. J Dermatol Sci 22 (2000) 102-106
3. Gu L.H., Ichiki Y., and Kitajima Y. Aberrant expression of p16 and RB protein in eccrine porocarcinoma. J Cutan Pathol 29 (2002) 473-479
4. Morton S., Davis R.J., and Cohen P. Signalling pathways involved in multisite phosphorylation of the transcription factor ATF-2. FEBS Lett 572 (2004) 177-183
5. Papassava P., Gorgoulis V.G., Papaevangeliou D., Vlahopoulos S., van Dam H., and Zoumpourlis V. Overexpression of activating transcription factor-2 is required for tumor growth and progression in mouse skin tumors. Cancer Res 64 (2004) 8573-8584
6. Bhoumik A., Ivanov V., and Ronai Z. Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment. Clin Cancer Res 2 (2001) 331-342
7. Horvath C.M. STAT proteins and transcriptional responses to extracellular signals. TIBS 25 (2000) 496-502
8. Ma X.T., Wang S., Ye Y.J., Du R.Y., and Cui Z.R. Relationship of Stat3 and its target gene products with malignancy in human colorectal carcinoma. Ai Zheng 22 (2003) 1135-1139
9. Lin N., Uchi H., Moroi Y., Fukiwake N., Dainichi T., Takeuchi S., et al. Expression of the p38 MAPK, NF-kappaB and cyclin D1 in extramammary Paget's disease. J Dermatol Sci 45 (2007) 187-192
10. Levy D.E., and Lee C.K. What does Stat3 do?. J Clin Invest 109 9 (2002) 1143-1148 (review)